Paminogen and Vibozone Jointly Develop New Drug Candidate Discovery

Paminogen and Vivoborn are set to embark on joint research and development of innovative new drugs using artificial intelligence (AI).

On the 24th, Paminogen, a company specializing in AI deep learning-based drug development, announced that it has signed a joint development partnership agreement with Vivoborn to discover new drug candidates.

Through this agreement, both companies will collaborate on medical application research and development to discover new drug candidates for various indications, including central nervous system and metabolic disease treatments, utilizing their respective platform technologies.

Paminogen will take overall responsibility for discovering new drug candidates based on its AI quantum mechanics-based software and the ultra-fast drug development platform Lucinet, built on bio big data. This includes virtual screening of active substances for target disease proteins, virtual synthesis of new drugs, prediction of drug-protein binding modes, and prediction of pharmacokinetics and toxicity. Vivoborn, with its strengths in small molecule drug development, will handle preclinical to clinical and commercialization stages, including efficacy testing, drug evaluation, and formulation research and development for the drug candidates discovered through the joint collaboration.

Lee Doohyun, Chairman of Vivoborn, stated, “By combining Paminogen’s AI technology with our small molecule drug development platform, we expect to improve the efficiency and technological capabilities of new drug development. In addition to the existing pipeline specialized in central nervous system diseases, we anticipate expanding to various other indications.”

Kim Younghoon, CEO of Paminogen, said, “By adopting our AI platform ‘Lucinet,’ Vivoborn will be able to reduce the time and cost required to discover new drug candidates for various indications, thereby maximizing the efficiency of new drug development.”